Chevy Chase Trust Holdings LLC Has $18.08 Million Stock Holdings in DexCom, Inc. $DXCM

Chevy Chase Trust Holdings LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 207,117 shares of the medical device company’s stock after acquiring an additional 2,204 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.05% of DexCom worth $18,079,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. SWS Partners bought a new position in DexCom in the 2nd quarter valued at approximately $1,661,000. Baader Bank Aktiengesellschaft bought a new position in DexCom in the 2nd quarter valued at approximately $393,000. Mn Services Vermogensbeheer B.V. lifted its stake in DexCom by 4.9% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after purchasing an additional 6,800 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in DexCom by 85.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after purchasing an additional 557,576 shares during the last quarter. Finally, Shell Asset Management Co. lifted its stake in DexCom by 16.8% in the 2nd quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock valued at $3,126,000 after purchasing an additional 5,138 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $66.60 on Friday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The firm has a fifty day simple moving average of $73.35 and a 200 day simple moving average of $77.58. The company has a market capitalization of $26.12 billion, a PE ratio of 46.25, a P/E/G ratio of 1.40 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm earned $0.43 earnings per share. DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Barclays raised their price target on shares of DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Piper Sandler raised their price target on shares of DexCom from $90.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Finally, Mizuho raised their price target on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $97.00.

Insider Activity

In related news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares of the company’s stock, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,849 shares of company stock worth $564,733 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.